Director/PDMR Shareholding
Summary by AI BETAClose X
Morgan Sindall Group plc (the "Company")
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
The following notification is intended to satisfy the Company's obligations under Article 19.3 of EU Regulation No 596/2014 (the Market Abuse Regulation).
|
1. |
Details of Restricted Person/person closely associated with them ("PCA") |
||||||||||
|
a) |
Name |
John Morgan (Chief Executive) Kelly Gangotra (Chief Financial Officer) |
|||||||||
|
2. |
Reason for the notification |
||||||||||
|
a) |
Position/status |
Members of the Board of directors |
|||||||||
|
b) |
Initial notification/amendment |
Initial notification |
|||||||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||||||
|
a) |
Name |
Morgan Sindall Group plc |
|||||||||
|
b) |
LEI |
2138008339ULDGZRB345 |
|||||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 5 pence each
ISIN: GB0008085614 |
|||||||||
|
b) |
Nature of the transaction |
Grant of conditional awards over Ordinary Shares on 9 March 2026, under the Company's 2023 Long Term Incentive Plan, adopted by the Company on 1 August 2023 ("2023 LTIP"). Each conditional award will vest on 9 March 2029 subject to the satisfaction of performance criteria. Each conditional award carries a right to receive, on vesting, an amount linked to dividends paid on the Ordinary Shares subject to the conditional award. The dividend equivalent can be settled in cash or Ordinary shares of the Company. The vesting of the award will also be subject to a two-year holding period whereby any vested shares (net of any tax liability) will be retained in the Company's appointed nominee in accordance with the Company's directors' remuneration policy. |
|||||||||
|
c) |
Price(s) and volume(s) |
|
|||||||||
|
d) |
Aggregated information - Aggregated volume - Price |
As above
|
|||||||||
|
e) |
Date of the transaction |
9 March 2026 |
|||||||||
|
f) |
Place of the transaction |
Outside a trading venue |
|||||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 19 minutes ago JPMorgan Emerging Markets Growth & Income plc
- 21 minutes ago National Grid
- 57 minutes ago City of London Investment Group
- 1 hour ago BioPharma Credit
- 1 hour ago BioPharma Credit